Progen Pharmaceuticals Limited - Product Pipeline Review – 2015 Is Released Progen Pharmaceuticals Limited - Product Pipeline Review - 2015 Summary Global Markets Direct s, Progen Pharmaceuticals Limited - Product Pipeline Review - 2015, provides an overview of the Progen Pharmaceuticals Limited s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Progen Pharmaceuticals Limiteds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides brief overview of Progen Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Progen Pharmaceuticals Limiteds human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on outlicensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Progen Pharmaceuticals Limiteds pipeline products Reasons to buy - Evaluate Progen Pharmaceuticals Limiteds strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Progen Pharmaceuticals Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Progen Pharmaceuticals Limited s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Progen Pharmaceuticals Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progen Pharmaceuticals Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business
1
potential and scope - Explore the dormant and discontinued projects of Progen Pharmaceuticals Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179148/progen-pharmaceuticals-limited-product-pipeline-review-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179148/progen-pharmaceuticals-limited-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Progen Pharmaceuticals Limited Snapshot 4 Progen Pharmaceuticals Limited Overview 4 Key Information 4 Key Facts 4 Progen Pharmaceuticals Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Progen Pharmaceuticals Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Progen Pharmaceuticals Limited - Pipeline Products Glance 9 Progen Pharmaceuticals Limited - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Progen Pharmaceuticals Limited - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 2
Discovery Products/Combination Treatment Modalities 12 Progen Pharmaceuticals Limited - Drug Profiles 13 muparfostat sodium 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 PG-545 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Progen Pharmaceuticals Limited - Pipeline Analysis 19 Progen Pharmaceuticals Limited - Pipeline Products by Target 19 Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration 20 Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type 21 Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 22 Progen Pharmaceuticals Limited - Recent Pipeline Updates 23 Progen Pharmaceuticals Limited - Dormant Projects 25 Progen Pharmaceuticals Limited - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 3
PG-562 26 Progen Pharmaceuticals Limited - Company Statement 27 Progen Pharmaceuticals Limited - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Progen Pharmaceuticals Limited Snapshot 4 Progen Pharmaceuticals Limited Overview 4 Key Information 4 Key Facts 4 Progen Pharmaceuticals Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Progen Pharmaceuticals Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 4
Pipeline Products - Monotherapy 8 Progen Pharmaceuticals Limited - Pipeline Products Glance 9 Progen Pharmaceuticals Limited - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Progen Pharmaceuticals Limited - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Progen Pharmaceuticals Limited - Drug Profiles 13 muparfostat sodium 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 PG-545 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Progen Pharmaceuticals Limited - Pipeline Analysis 19 5
Progen Pharmaceuticals Limited - Pipeline Products by Target 19 Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration 20 Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type 21 Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 22 Progen Pharmaceuticals Limited - Recent Pipeline Updates 23 Progen Pharmaceuticals Limited - Dormant Projects 25 Progen Pharmaceuticals Limited - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 PG-562 26 Progen Pharmaceuticals Limited - Company Statement 27 Progen Pharmaceuticals Limited - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31 Read More http://www.idatainsights.com/reports-landing-page.php?id=179148/progenpharmaceuticals-limited-product-pipeline-review-2015 About Us: 6
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
7